Feedback / Questions
OPM-101 - Oncodesign
https://www.businesswire.com/news/home/20250324831272/en/Oncodesign-Precision-Medicine-OPM-Announces-Protocol-Submission-for-its-Phase-1b2a-Study-REVERT-for-OPM-101-in-Combination-with-Pembrolizumab-in-Patients-with-Advanced-Melanoma-Resistant-to-Anti-PD1
Mar 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next